UNDERSTAND PATIENTS WITH SIMULATED CELLS™


UNLOCK CURES

FIND THE BEST RESPONDERS

OVERCOME RESISTANCE

RATIONALIZE R&D
Alan Barge
Alan Barge
ex VP and Head of Oncology and Infection at AstraZeneca
“Turbine can fundamentally change the way in which novel targets in precision oncology are identified.”
David M. Rubin, Ph.D.
David M. Rubin, Ph.D.
Managing Director of MSD Global Health Innovation Fund
“We believe Turbine’s Simulated Cell has the potential to transform key aspects of the oncology drug discovery and development process, providing insight at scale that will shed light on even the most challenging biological mechanisms.”

SIMULATIONS CAPTURE PATIENT BIOLOGY WHERE EXPERIMENTS FAIL

Drag / scroll horizontally for more

DRUG DISCOVERY IS LIMITED BY OUR TOOLS TO UNDERSTAND DISEASE

The complexity of the model systems sharply increases along the drug discovery process, while only a limited number of experimental models are available that accurately reflect human disease.

Conventional in vitro and in vivo models cannot capture disease behavior in real patients, and tools – like CRISPR – don’t act like actual drugs. Drug discovery is costly, time consuming, model systems have poor translation rates to patients and do not significantly reduce the risk of failure in the clinic. This makes it incredibly hard to translate preclinical hypotheses to the clinic and create targeted drugs that truly help.

SIMULATIONS UNCOVER TREATMENTS AND THE PATIENTS WHO BENEFIT

Before running any wet lab experiments, Turbine computationally simulates tumor cell behavior in patients to understand the complex mechanisms driving the disease. Simulations can reveal the right modality and combination approach to treat even the most resistant cancers. Observing these in silico experiments our biologists and translational experts gain insight into the molecular context by which mono- and combination therapies can potentially lead to patient benefit.

Guiding the R&D process with simulations can increase the chance of success in the clinic.

https://pubmed.ncbi.nlm.nih.gov/14518029/
https://www.nature.com/articles/s41467-021-25175-5
globaldata.com

    ENGINEERING A WAY TO UNDERSTAND BIOLOGY

    1
    Model building and training
    Wiring

    We use the same “wiring diagram” for all 1600+ in vitro and in vivo models, with patient modeling currently under development.

    2
    Model building and training
    Cell specification

    Our bioplatform allows the setup of cells with distinct OMICS profiles. Behavior training for the models is a special case of Recurrent Neural Networks, using Tensorflow.

    Models prepared for simulations are trained on 500.000+ data points (CRISPR, drug sensitivity viability and post-treatment RNASeq assays).

    3
    Model building and training
    Biomarkers

    We finish model setup by creating copies with different biomarkers to pinpoint the ideal responders for the specific perturbations.

    We can specify extrinsic molecular alterations, to generate a high number of models representative of patients, but non-existent in vitro.

    4
    Simulation and hypotheses generation
    Therapy

    We can introduce interventions at scale, using a versatile toolkit of dose dependent inhibition, interaction level perturbation or combination screens.

    5
    Simulation and hypotheses generation
    Simulation

    Simulating perturbations of models, biomarkers and (even) combinational therapies we generate a complex molecular readout of dose responses and IC50 values.

    6
    Simulation and hypotheses generation
    Translation

    Filtering and evaluating simulation results enables us to reveal hidden mechanisms behind patient-specific response and its driving effects.

    7
    Experimental validation

    Unique insights on mechanism and the associated biomarkers enable an optimized process of state-of-the-art experimental validation.
    Average pathway activity in sensitive and control cells is calculated with a proprietary, footprint-based method based on RNA-sequencing.

    1
    Model building and training
    Wiring

    We use the same “wiring diagram” for all 1600+ in vitro and in vivo models, with patient modeling currently under development.

    2
    Model building and training
    Cell specification

    Our bioplatform allows the setup of cells with distinct OMICS profiles. Behavior training for the models is a special case of Recurrent Neural Networks, using Tensorflow.

    Models prepared for simulations are trained on 500.000+ data points (CRISPR, drug sensitivity viability and post-treatment RNASeq assays).

    3
    Model building and training
    Biomarkers

    We finish model setup by creating copies with different biomarkers to pinpoint the ideal responders for the specific perturbations.

    We can specify extrinsic molecular alterations, to generate a high number of models representative of patients, but non-existent in vitro.

    4
    Simulation and hypotheses generation
    Therapy

    We can introduce interventions at scale, using a versatile toolkit of dose dependent inhibition, interaction level perturbation or combination screens.

    5
    Simulation and hypotheses generation
    Simulation

    Simulating perturbations of models, biomarkers and (even) combinational therapies we generate a complex molecular readout of dose responses and IC50 values.

    6
    Simulation and hypotheses generation
    Translation

    Filtering and evaluating simulation results enables us to reveal hidden mechanisms behind patient-specific response and its driving effects.

    7
    Experimental validation

    Unique insights on mechanism and the associated biomarkers enable an optimized process of state-of-the-art experimental validation.
    Average pathway activity in sensitive and control cells is calculated with a proprietary, footprint-based method based on RNA-sequencing.

    THE WORLD’S FIRST INTERPRETABLE CELL SIMULATION PLATFORM AUGMENTED BY MACHINE LEARNING

    Pioneering an approach that combines simulation with machine learning, we map and model how thousands of signaling proteins interact characterizing cellular level cancer behavior and response or resistance to treatment.

    Our platform enables the simulation of drug-like effects from compounds that may not exist yet, on cells potentially unavailable for lab-based testing, like those of high unmet need cancer patients.

    PREDICT NOVEL EXPERIMENTS TO FIND DRUGS NO-ONE HAS EVER THOUGHT OF

    This approach will potentially allow us to predict not only what works in cells, mice and people but more importantly, why and how. Continuous iterations of simulations and proprietary in vitro and in vivo experiments confirm predictions and progress our pipeline while simultaneously improving the underlying Simulated Cell™.

    As all programs and partnerships run on the latest version of the in silico cell model, training benefits accumulate, leading to a constantly improving platform. Using results to both generate the initial idea and to guide its iterations, as the models improve, this leads to a more rational process to undestand the underlying disease biology.

    Our benchmarks show that simulations prevent 2 out of 3 failed experiments in vitro and every 2nd failure in vivo as well.

      A SINGLE PLATFORM TO RATIONALIZE THE ENTIRE R&D PROCESS

      PREDICT UNSEEN BIOLOGY AND EXPLORE ALL EXPERIMENTAL OPTIONS
      TO UNDERSTAND RESPONSE AND RESISTANCE

      Understanding the disease

      Simulating cancer behavior to understand drivers of disease & mechanisms of resistance observed in clinical settings.

      Finding the ideal patients

      Uncovering ideal patient population and combination strategy for therapies already in development or on the market.

      Expanding the search space

      Identifying truly novel targets to manage unmet need in patients who don’t benefit from existing therapies.

      Past collaborations
      Drag / scroll horizontally for more

      Discovery

      Target ID and Mechanistic profiling

      Novel target – biomarker packages for high unmet need patients.

      High throughput biological profiling of hit & lead compounds.

      Translational

      Disease positioning

      Drug target profiling, indication selection, patient stratification and biomarkers.

      Clinical

      Indication expansion

      Selection of biomarkers and combinations to overcome resistance and expand indication space.

      Contact Us

        BUILDING DEEP TECH FOR DEEP BIOLOGY

        Building an engineer’s toolkit to understand biology requires software and data scientists who wish to enable biological translational science instead of replacing it.

        Our team combines the amazing molecular biology, network- and data science expertise in Hungary with seasoned drug developers from the UK and the US. We’re here to change the status quo and bring truly impactful, simulation-guided therapies to patients.

        Csaba
        Head of Legal
        Szabi
        VP of Engineering
        Bence
        Research Team Lead
        Dóri
        Associate Scientist
        SzaCsa
        Senior Bioscientist
        Eszter
        Translational Scientist & Junior Data Analyst
        Réka
        Junior Data Scientist
        Robi
        Engineering Lead
        Valér
        Senior Data Scientist
        Tomi
        Bioinformatician
        Csilla
        Chief of Staff
        Gerold
        Senior Model Developer
        Zsófi
        VP of Product
        Miki
        Senior Bioinformatician Scientist
        Lilla
        Senior Talent Acquisition Specialist
        Eff
        Senior Software Engineer
        Balázs
        Engineering Lead
        Dorina
        Lab Scientist
        Segó
        Senior Software Engineer
        Bálesz
        Head of Marketing Communications
        Andris
        Software Engineer
        Centi
        Research Team Lead
        Dóri
        Product Manager
        Bálint
        Engineering Lead
        Szabi
        Chief Executive Officer
        Anna
        VP of HR
        Tomi
        Head of Business Development
        Ági
        People Operations Specialist
        Árpi
        Associate Scientist
        Bea
        Group Finance Manager
        Iván
        Translational Scientist
        Orsi
        Product Manager
        Kris
        Chief Technology Officer
        Dani
        Chief Scientific Officer
        Boldi
        Head of Pipeline Development
        Edit
        Financial Controller
        Bob
        Chief Business Officer
        Milán
        Senior Model Developer
        Imi
        Senior Bioinformatician Scientist
        Csilla
        Senior Project Manager
        Engineering Lead

        “Turbine is one of those rare places where a software engineer can have literally lifesaving impact. We work closely with the researchers and witness every day how they use our platform to get better and better predictions. The tech stack is cutting edge: cloud, AI, big data aren’t just buzzwords but practical tools we need to use. And as an added bonus, we get to learn about biology, medicine, and how scientific research works organically – just by being exposed to it constantly!”

        more
        collapse
        Translational Scientist & Junior Data Analyst

        “Working here has been quite a journey since day one. Not only the substantial progress we’ve achieved so far, but also personally: as a biologist, I was lured into the field of data analysis. We also have the most inspiring community, with talented and ‘crazy’ people. I’m really a Turbine-addict.”

        more
        collapse
        Associate Scientist

        “Upon joining I immediately started to like Turbine’s multidisciplinary vibe, which I had already got used to during my MSc studies with peers of different professional backgrounds. The fundamental knowledge from my studies proved to be essential for starting as a Cell Developer and later specializing as a Translational Biologist. For me as a social soul, the community was always and still is very important. Just like in the university, many relationships turned into important friendships with my current colleagues.”

        more
        collapse
        VP of HR

        “Turbine is an amazing community from various fields and backgrounds, working on the verge of current human knowledge, breaking barriers to succeed where no one else has even attempted to. We do this with relentless curiosity, healthy scepticism, knowing our strength is in our differences, and this inspires me day by day.”

        more
        collapse
        Join our mission

        FOUNDERS AND LEADERSHIP

        Co-Founder
        Chief Executive Officer, Founder Director

        Szabi leads a team of 60+ data scientists, computational and molecular biologists drawn from Budapest’s deep tech talent pool. A serial entrepreneur, Nagy cofounded Turbine in 2015 after launching a cybersecurity startup which was subsequently acquired. Although lacking biotech industry expertise at the time, Szabi has since steered Turbine through multiple top-20 pharma partnerships and financing rounds. Turbine most recently closed a €20M Series A round co-led by Merck’s Global Health Innovation Fund, a unique achievement in Hungary’s small lifesci community.

        more
        collapse
        Founder
        Chief Technology Officer

        A computer scientist turned biochemist, Kristóf’s dream is to turn biology into an engineering discipline, enabling science to create human organs as efficiently as we make cars. Named one of the 35 Innovators under 35 in 2018 by MIT Tech Review Europe, Kristóf invented Turbine’s method of simulating human cells and is leading the R&D teams working on the Simulated Cell to make more and more hidden biology available to our internal and external projects.

        more
        collapse
        Co-Founder
        Chief Scientific Officer

        As a medical doctor specializing in cancer research at some of the world’s top research institutes, Daniel helps design innovative and durable treatments against cancer by converting our platform’s computational results into clinical interpretations. His main responsibility lies in understanding scientific and medical challenges, to then guide our team of biologists, translational and data scientists in generating novel findings to move better treatments to patients.

        more
        collapse
        Chief Business Officer
        VP of Finance
        Chief of Staff

        BOARD AND ADVISORS

        Independent Director, Chair
        General Partner at Bristlecone Pacific
        Independent Director
        CBO at Verge Genomics
        Independent Director
        Board Member, Chairman & Entrepreneur,
        former CEO & Sr. Exec. in multiple Biotech
        and Pharma corps.
        Independent Director
        Co-Founder and COO of Paradigm
        Investor Director
        Managing Partner at MassMutual Ventures
        Investor Director
        Partner at Delin Ventures
        Investor Director
        Healthcare Investment Director
        at Mercia Asset Management
        Professor of Cell, Developmental and Cancer Biology,
        School of Medicine at Oregon Health & Science University
        Chief Scientific Officer andCo-Founder
        at Nested Therapeutics
        ex Global Head of R&D at Merck Serono and
        ex Global Medical SVPat Bristol Myers Squibb
        ex VP of Clinical Oncology and
        ex Head of Oncology & Infectionat AstraZeneca
        ex Executive Director of the Medicinal Chemistry Unit
        for Oncology of Novartis
        ex Associate Director ofCancer Data Science
        at Broad Institute
        ex Global Head of Research Platformsat Sanofi,
        ex Oncology Drug Discovery Head at Novartis
        Prof. for Molecular Informatics at University of Cambridge, CITO at Pangea Botanica

        UNDERSTAND PATIENTS WITH SIMULATED CELLS™


        UNLOCK CURES


        FIND THE BEST RESPONDERS


        OVERCOME RESISTANCE


        RATIONALIZE R&D

        PARTNERS AND INVESTORS
        All rights reserved ©2024 Turbine Ltd.  |   Privacy Policy  |   Created by Art&Board Studio